Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice

Metabolism: Clinical and Experimental

Volumn 58, Issue 3, 2009, Pages 379-386

  Matsuyama Yokono, Akiko ^a   Tahara, Atsuo ^a   Nakano, Ryosuke ^a   Someya, Yuka ^a   Shiraki, Katsuhisa ^a   Hayakawa, Masahiko ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ASP 8497; GLIBENCLAMIDE; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLICLAZIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; GLYBURIDE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED ICR; NIACINAMIDE; PIPERIDINES; PYRROLIDINES; SULFONYLUREA COMPOUNDS;

EID: 59649108238     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.10.012     Document Type: Article

References (33)

1. Cavaghan M.K., Ehrmann D.A., and Polonsky K.S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106 (2000) 329-333
2. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care 15 (1992) 737-754
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352 (1998) 837-853
4. Holman R.R. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 55 (2006) S2-S5
5. Asplund K., Wiholm B.E., and Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24 (1983) 412-417
6. Stahl M., and Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 16 (1999) 586-590
7. Pontiroli A.E., Calderara A., and Pozza G. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev 10 (1994) 31-43
8. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., and Turner R.C. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 15 (1998) 297-303
9. Hosokawa Y.A., and Leahy J.L. Parallel reduction of pancreas insulin content and insulin secretion in 48-h tolbutamide-infused normoglycemic rats. Diabetes 46 (1997) 808-813
10. Leahy J.L. Impaired β-cell function with chronic hyperglycemia: 'overworked β-cell' hypothesis. Diabetes Rev 4 (1996) 298-319
11. Taverna M.J., Pacher N., Bruzzo F., Slama G., and Selam J.L. Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in type 2 diabetes. Diabet Med 18 (2001) 584-588
12. + channel activity. Diabetes 48 (1999) 2001-2006
13. Gromada J., Brock B., Schmitz O., and Rorsman P. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential. Basic Clin Pharmacol Toxicol 95 (2004) 252-262
14. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 87 (2007) 1409-1439
15. MacDonald P.E., El-Kholy W., Riedel M.J., Salapatek A.M., Light P.E., and Wheeler M.B. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 51 (2002) S434-S442
16. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85 (1999) 9-24
17. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
18. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44 (1995) 1126-1131
19. Gutniak M., Orskov C., Holst J.J., Ahren B., and Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326 (1992) 1316-1322
20. Toft-Nielsen M.B., Damholt M.B., Madsbad S., Hilsted L.M., Highes T.E., Michelsen B.K., et al. Determinations of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86 (2001) 3717-3723
21. Pederson R.A., White H.A., Schlenzig D., Pauly R.P., McIntosh C.H., and Demuth H.U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47 (1998) 1253-1258
22. Reimer M.K., Holst J.J., and Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 146 (2002) 717-727
23. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
24. Rosenstock J., Baron M.A., Dejager S., Mills D., and Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30 (2007) 217-223
25. Someya Y., Tahara A., Nakano R., Matsuyama-Yokono A., Nagase I., Fukunaga Y., et al. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 377 (2008) 209-217
26. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., et al. 1-[[(3-Hydroxy-1-adamantyl]amino)acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46 (2003) 2774-2789
27. Polonsky K.S., Given B.D., Hirsch L.J., Tillil H., Shapiro E.T., Beebe C., et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318 (1988) 1231-1239
28. Matsuyama-Yokono A., Tahara A., Nakano R., Someya Y., Nagase I., Hayakawa M., et al. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol 76 (2008) 98-107
29. Gold G., Pou J., Gishizky M.L., Landahl H.D., and Grodsky G.M. Effects of tolbutamide pretreatment on the rate of conversion of newly synthesized proinsulin to insulin and the compartmental characteristics of insulin storage in isolated rat islets. Diabetes 35 (1986) 6-12
30. Sako Y., and Grill V.E. Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 39 (1990) 1580-1583
31. Brubaker P.L., and Drucker D.J. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145 (2004) 2653-2659
32. List J.F., and Habener J.F. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am J Physiol 286 (2004) E875-E881
33. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., and Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 (2003) 471-478